Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 3,919 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $334,290.70. Following the completion of the transaction, the chief operating officer owned 73,810 shares of the company’s stock, valued at $6,295,993. This represents a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kymera Therapeutics Stock Down 0.3%

Shares of KYMR traded down $0.24 during mid-day trading on Wednesday, hitting $86.11. 1,043,150 shares of the company traded hands, compared to its average volume of 845,289. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00. The stock has a 50-day moving average price of $78.69 and a two-hundred day moving average price of $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. Kymera Therapeutics’s quarterly revenue was down 60.8% on a year-over-year basis. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

KYMR has been the topic of several analyst reports. Mizuho lifted their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Barclays raised their target price on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a report on Monday, December 8th. HC Wainwright raised their price objective on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $119.50.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP grew its stake in Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP purchased a new position in Kymera Therapeutics during the 3rd quarter valued at approximately $47,563,000.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target to $128 and maintained a Buy rating, implying meaningful upside vs. the current level — this is a material analyst catalyst that can support upside interest. UBS price target raise
• Positive Sentiment: Analyst coverage and commentary highlight Kymera’s strong cash position (~$1.6B) and advancing degraders (KT‑621, KT‑579) into mid‑stage trials — these program milestones (2026–2027 catalysts) underpin medium‑term upside. Seeking Alpha pipeline write-up
• Positive Sentiment: Recent press roundups note broad analyst bullishness on select healthcare names including Kymera, which can help sustain investor interest from institutions and momentum traders. Globe and Mail analyst roundup
• Neutral Sentiment: Fundamentals remain mixed: recent quarterly results included a revenue shortfall and wider losses, which keep near‑term valuation sensitive to execution and clinical readouts. (Context referenced in analyst coverage above.) Seeking Alpha: financial context
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M) — a ~10.8% reduction in his holding — which is a notable insider disposition that may create near‑term selling pressure or prompt investor questions about timing. Bruce Booth Form 4
• Negative Sentiment: Multiple executive sales: CFO Bruce Jacobs, COO Jeremy Chadwick and insider Jared Gollob completed several transactions across March 2–4 totaling tens of thousands of shares at prices in the mid‑$80s to ~$90 — cumulative insider selling raises short‑term supply concerns. Insider filings

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.